Healthcare / Medical Instruments & SuppliesTokyo
$424.00
-6.00 (-1.40%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-1.1B · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$10.4B
P/E
116.2x
↑EV/EBITDA
6.1x
↓ROE
0.2%
↓Gross Margin
22.8%
↓Debt/Equity
0.60
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.2%
FCF CAGR
—
FCF margin
-2.3%
FCF / Net income
-17.67x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $69.75B · net income $89.0M · FCF $-1.57B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $69.75B | $69.75B | $65.29B | $63.74B | $58.17B |
| Net Income | $89.0M | $89.0M | $-36.0M | $281.0M | $826.0M |
| EBITDA | $4.79B | $4.79B | $4.08B | $4.38B | $4.59B |
| EPS | 3.65 | 3.65 | -1.48 | 11.50 | 33.83 |
| Gross Margin | 22.8% | 22.8% | 21.6% | 22.9% | 24.5% |
| Operating Margin | 1.3% | 1.3% | -0.4% | 1.1% | 1.7% |
| Net Margin | 0.1% | 0.1% | -0.1% | 0.4% | 1.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.60 | 0.60 | 0.66 | 0.51 | 0.51 |
| Current Ratio | 1.78 | 1.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.57B | $-1.57B | $498.0M | $-1.07B | $1.14B |
| Returns | |||||
| ROE | 0.2% | 0.2% | -0.1% | 0.7% | 2.2% |
| Valuation | |||||
| P/E | 116.16 | 116.16 | — | 44.09 | 17.79 |
| EV/EBITDA | 6.14 | 6.14 | 7.21 | 5.89 | 5.84 |
| P/B | 0.25 | 0.25 | 0.32 | 0.32 | 0.40 |
| Growth & Yield | |||||
| Revenue Growth | 6.8% | 6.8% | 2.4% | 9.6% | — |
| EPS Growth | 346.6% | 346.6% | -112.9% | -66.0% | — |
| Dividend Yield | 4.0% | 4.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
117.6%
EPS terminal req.
$37.62
Spread vs growth
229.0%
5Y implied EPS CAGR
65.6%
EPS terminal req.
$45.52
Spread vs growth
281.0%
10Y implied EPS CAGR
35.0%
EPS terminal req.
$73.32
Spread vs growth
311.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+4.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.48 → 3.65
Residual
+0.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.